跨国药企半年报:冰火两重天,创新突围战打响

21世纪经济报道
Aug 12

8月以来,包括强生、艾伯维、默沙东、罗氏、辉瑞、阿斯利康、诺华、百时美施贵宝、诺和诺德等在内的跨国药企均已公开2025年上半年的财报。从财报数据不难看出,一些制药公司以优异的成绩通过了考核,也有不少制药企业经历了业绩下滑,也有些是在第二季度遭遇困境。  这也是由于在专利到期、市场竞争加剧及政策调整压力的多重作用下,跨国药企的业绩呈现出“冰火两重天”的分化态势。这更意味着全球制药行业已逐渐告别“黄金...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10